About this trial
Delayed graft function (DGF), delineated by the necessity for dialytic intervention within the initial week post-transplantation, afflicts approximately 20%-50% of recipients. The primary objective of this study is to investigate the potential efficacy of norepinephrine infusion in conjunction with goal-directed fluid therapy (GDFT) in mitigating the occurrence of DGF among individuals undergoing kidney transplantations. The findings of this investigation have the potential to advance the field of perioperative care in kidney transplantations by providing insights into optimized management strategies.
Eligibility criteria
Qualifiers
Recipients aged 18 years or older
Scheduled to undergo kidney transplantations under general anesthesia
Cadaveric kidney transplantations
Sign the informed consent form
Disqualifiers
Donors aged under 18 years
Donor kidneys classified as Maastricht category I or II
Contraindications to radial artery catheterization
Pregnancy
Trial design
Treatments tested in this trial
- Goal-Directed Fluid Therapy (GDFT)
- Regular Fluid Therapy